Vertaling van "12 months " (Frans → Nederlands) :

TERMINOLOGIE

Salmonella II 1,4,12:z29:e,n,x
Salmonella II 1,4,12:z29:e,n,x

Salmonella II 4,12:l,w:e,n,x
Salmonella II 4,12:l,w:e,n,x

Salmonella II 1,4,12,27:b:[e,n,x]
Salmonella II 1,4,12,27:b:[e,n,x]

Salmonella II 1,4,12,27:g,,t:[1,5]
Salmonella II 1,4,12,27:g,,t:[1,5]

paraplégie spastique autosomique dominante type 12
autosomaal dominante spastische paraplegie type 12

Salmonella II 1,9,12:l,w:e,n,x
Salmonella II 1,9,12:l,w:e,n,x

accident exigeant une attention médicale dans les derniers 12 mois
ongeval dat in laatste 12 maanden medische aandacht vereiste

syndrome de microdélétion 19p13.12
del(19)(p13.12)

trisomie 12
trisomie 12

Salmonella II 1,4,12,27:z39:1,[5],7
Salmonella II 1,4,12,27:z39:1,[5],7

IN-CONTEXT TRANSLATIONS

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Raloxifen for prevention of glucocorticoid-induced bone loss: a 12-month randomized double-blinded placebo-controlled trial.
Raloxifen for prevention of glucocorticoid-induced bone loss: a 12-month randomized doubleblinded placebo-controlled trial.

The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than lowintensity, particularly with nicotine gum, although this was of no significance.
The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than low-intensity, particularly with nicotine gum, although this was of no significance.

* Source : Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age : a systematic review, Denise Harrison & coll., Archives of Disease in Childhood, 2010.
* Bron: Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age : a systematic review (De doeltreffendheid van suikeroplossingen als pijnstiller bij kinderen van 1 tot 12 maanden: een systematisch overzicht), Denise Harrison & coll., Archives of Disease in Childhood, 2010.

considérations sur les différentes méthodes utilisées pour la désinfection des piscines In this scientific advisory report to policy makers, the Superior Health Council reflects on chlorine and alternative methods for swimming pool disinfection and infection control and, in doing so, focuses on the particular target group of young infants (0-12 month-old baby swimmers).
In this scientific advisory report to policy makers, the Superior Health Council reflects on chlorine and alternative methods for swimming pool disinfection and infection control and, in doing so, focuses on the particular target group of young infants (0-12 month-old baby swimmers).